KLK3 and prostate carcinoma: Prostate cancer has shown a levelling-off in its mortality rate which is most likely due to the introduction of early screening for the prostate-specific antigen (PSA) biomarker (Fig. 2) (ECIS, 2018; Heijnsdijk et al., 2018; Torre et al., 2015).